HLA-G Expression Is an Independent Predictor for Improved Survival in High Grade Ovarian Carcinomas

Table 1

Patient characteristics.

Baseline characteristics	All patients; (𝑛=169)
Mean age, years (SD)	61 (11.7)
FIGO stage
I	8 (5%)
II	7 (4%)
III	125 (74%)
IV	29 (17%)
Histologic classification
High grade serous	141 (83%)
Undifferentiated	28 (17%)
Residual disease after debulking surgery
No macroscopic tumour	37 (22%)
Less than 1 cm residual disease	46 (27%)
1 cm or more residual disease	86 (51%)
Kind of debulking surgery
PDS	134 (79%)
IDS	35 (21%)
Tissue origin
Ovary	141
Metastases	28
Kind of chemotherapy given
None	9 (5%)
Single drug platinum	5 (3%)
Multidrug carboplatin/paclitaxel	123 (19%)
Multidrug with platinum	32 (73%)
Amount of cycles	6 (5–7)
Platinum sensitivity
Refractory disease	34 (20%)
Platinum resistant disease	36 (21%)
Partial chemosensitive	25 (15%)
Platinum sensitive disease	65 (38%)

Refractory disease: recurrence occurred during chemotherapy treatment; platinum resistant disease: recurrence occurred within 6 months after the last cycle of chemotherapy; partial platinum sensitive disease: recurrence occurred after 6 months or within 1 year after last cycle of platinum based chemotherapy; platinum sensitive disease: recurrence occurred more than 1 year after the last cycle of chemotherapy.